Sprifermin - Merck

Drug Profile

Sprifermin - Merck

Alternative Names: AS-902330; FGF-18; rhFGF-18; Zfgf5

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZymoGenetics
  • Developer Merck Serono; Molecular Therapeutics; Nordic Bioscience; Pfizer
  • Class Fibroblast growth factors; Neuroprotectants
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Discontinued Cartilage disorders; Stroke

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Dec 2017 Updated efficacy data from phase II trial in Osteoarthritis presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
  • 04 Nov 2017 Efficacy and adverse events data from phase II trial in osteoarthritis released by Merck
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top